Mantle Cell Lymphoma

Oncology
19
Pipeline Programs
16
Companies
24
Clinical Trials
7 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
3
11
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
343%
Monoclonal Antibody
229%
Cell Therapy
114%
Peptide
114%
+ 14 programs with unclassified modality

Competitive Landscape

16 companies ranked by most advanced pipeline stage

InnoCare
InnoCareChina - Beijing
3 programs
1
1
1
OrelabrutinibPhase 3Small Molecule1 trial
Orelabrutinib High dosePhase 21 trial
ICP-022Phase 1/21 trial
Active Trials
NCT03494179Unknown120Est. Dec 2023
NCT05978739Unknown40Est. May 2025
NCT06363994Recruiting476Est. Jun 2032
BeOne Medicines
BeOne MedicinesCA - San Carlos
2 programs
1
1
SonrotoclaxPhase 31 trial
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT07341191Not Yet RecruitingEst. Dec 2030
NCT06742996Recruiting300Est. Mar 2032
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
AcalabrutinibPhase 2Small Molecule1 trial
A Disease Registry of Patients With Mantle Cell LymphomaN/A1 trial
Active Trials
NCT03816683Completed227Est. Mar 2024
NCT05004064Recruiting48Est. Dec 2028
Genentech
GenentechCA - Oceanside
2 programs
1
1
VenetoclaxPhase 21 trial
GlofitamabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06192888Recruiting39Est. Jan 2028
NCT03834688Completed33Est. Jul 2024
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
AT7519MPhase 21 trial
Active Trials
NCT01652144CompletedEst. Feb 2015
Teva
TevaIsrael - Petach Tikva
1 program
1
BendamustinePhase 21 trial
Active Trials
NCT00891839Completed45Est. May 2014
Biogen
BiogenCAMBRIDGE, MA
1 program
1
FludarabinePhase 21 trial
Active Trials
NCT00119730Completed30Est. Dec 2013
Takeda
TakedaTOKYO, Japan
1 program
1
IxazomibPhase 21 trial
Active Trials
NCT03616782Recruiting98Est. May 2026
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
ObinutuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06252675Recruiting30Est. Jul 2028
CP
Chugai PharmaJapan - Tokyo
1 program
1
RiBVDPhase 2
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Venetoclax Oral Tablet [Venclexta]Phase 21 trial
Active Trials
NCT05025423Terminated7Est. May 2025
CT
1 program
1
400mg of TQB3909 tabletsPhase 1/21 trial
Active Trials
NCT06106841TerminatedEst. Oct 2024
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
Biospecimen CollectionPhase 1/21 trial
Active Trials
NCT06357676Recruiting27Est. Nov 2029
Bio-Path Holdings
Bio-Path HoldingsBELLAIRE, TX
1 program
1
L-Bcl-2 antisense oligonucleotidePhase 1Peptide1 trial
Active Trials
NCT04072458Active Not RecruitingEst. Apr 2025
Pfizer
PfizerNEW YORK, NY
1 program
1
PD 0332991Phase 15 trials
Active Trials
NCT02101034Completed96Est. Nov 2023
NCT01723774Active Not Recruiting84Est. Aug 2026
NCT01701375Terminated2Est. Apr 2013
+2 more trials
GS
Gilead SciencesFOSTER CITY, CA
1 program
Brexucabtagene AutoleucelN/ACell Therapy1 trial
Active Trials
NCT05776134Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BeOne MedicinesSonrotoclax
InnoCareOrelabrutinib
BeOne MedicinesZanubrutinib
Eli Lilly and CompanyObinutuzumab
AstraZenecaAcalabrutinib
InnoCareOrelabrutinib High dose
AbbVieVenetoclax Oral Tablet [Venclexta]
GenentechVenetoclax
TakedaIxazomib
PfizerPD 0332991
Astex PharmaceuticalsAT7519M
PfizerPD 0332991
TevaBendamustine
BiogenFludarabine
Knight TherapeuticsBiospecimen Collection

Showing 15 of 23 trials with date data

Clinical Trials (24)

Total enrollment: 1,725 patients across 24 trials

NCT06742996BeOne MedicinesSonrotoclax

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Start: Mar 2025Est. completion: Mar 2032300 patients
Phase 3Recruiting
NCT06363994InnoCareOrelabrutinib

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Start: May 2024Est. completion: Jun 2032476 patients
Phase 3Recruiting
NCT07341191BeOne MedicinesZanubrutinib

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Start: Mar 2026Est. completion: Dec 2030
Phase 2Not Yet Recruiting
NCT06252675Eli Lilly and CompanyObinutuzumab

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Start: Jun 2024Est. completion: Jul 202830 patients
Phase 2Recruiting
NCT05004064AstraZenecaAcalabrutinib

Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

Start: Nov 2023Est. completion: Dec 202848 patients
Phase 2Recruiting
NCT05978739InnoCareOrelabrutinib High dose

Evaluating Different Doses of Orelabrutinib in MCL

Start: Aug 2023Est. completion: May 202540 patients
Phase 2Unknown
NCT05025423AbbVieVenetoclax Oral Tablet [Venclexta]

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Start: Jun 2022Est. completion: May 20257 patients
Phase 2Terminated
NCT03834688GenentechVenetoclax

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Start: Jan 2020Est. completion: Jul 202433 patients
Phase 2Completed
NCT03616782TakedaIxazomib

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Start: Dec 2018Est. completion: May 202698 patients
Phase 2Recruiting
NCT01723774PfizerPD 0332991

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Start: Apr 2013Est. completion: Aug 202684 patients
Phase 2Active Not Recruiting
NCT01652144Astex PharmaceuticalsAT7519M

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Start: Sep 2012Est. completion: Feb 2015
Phase 2Completed
NCT01227434PfizerPD 0332991

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

Start: Sep 2010Est. completion: Dec 201323 patients
Phase 2Terminated
NCT00891839TevaBendamustine

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

Start: Jun 2009Est. completion: May 201445 patients
Phase 2Completed
NCT00119730BiogenFludarabine

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Start: Feb 2005Est. completion: Dec 201330 patients
Phase 2Completed
NCT06357676Knight TherapeuticsBiospecimen Collection

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Start: May 2025Est. completion: Nov 202927 patients
Phase 1/2Recruiting
NCT06106841Chia Tai TianQing Pharmaceutical Group400mg of TQB3909 tablets

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Start: Oct 2023Est. completion: Oct 2024
Phase 1/2Terminated
NCT03494179InnoCareICP-022

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Start: Apr 2018Est. completion: Dec 2023120 patients
Phase 1/2Unknown
NCT02101034PfizerPD 0332991

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Start: Jun 2014Est. completion: Nov 202396 patients
Phase 1/2Completed
NCT06192888GenentechGlofitamab

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Start: Jan 2024Est. completion: Jan 202839 patients
Phase 1Recruiting
NCT04072458Bio-Path HoldingsL-Bcl-2 antisense oligonucleotide

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Start: Nov 2020Est. completion: Apr 2025
Phase 1Active Not Recruiting
NCT01701375PfizerPD 0332991

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Start: Sep 2012Est. completion: Apr 20132 patients
Phase 1Terminated
NCT01111188PfizerPD 0332991

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Start: Aug 2010Est. completion: Apr 2019
Phase 1Terminated
NCT05776134Gilead SciencesBrexucabtagene Autoleucel

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

N/AAvailable
NCT03816683AstraZenecaA Disease Registry of Patients With Mantle Cell Lymphoma

A Disease Registry of Patients With Mantle Cell Lymphoma

Start: Apr 2019Est. completion: Mar 2024227 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 1,725 patients
16 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)